Clinical trials: Sjogren's Disease
Bullous Keratopathy, Corneal Erosion
AONDA Therapeutic Indication Study I
This study will be used to support assessment of AIR OPTIX® NIGHT \& DAY® AQUA (AONDA) Soft Contact Lenses' safety and performance in accordance with updated European Union Medical Device Regulation (EU MDR) requirements.
- Conditions
- Bullous Keratopathy, Corneal Erosion, Entropion, Corneal Edema
- Trial name
- NCT05891106
- Testing
- Lotrafilcon A contact lenses
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Alcon Research
Sjogren's Syndrome
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).
- Trial name
- NCT06312020
- Testing
- HZN-1116
- Where
- 66 sites in United States, Argentina and 14 more
- Volunteers
- 209 people
- Sponsor
- Amgen
Sjogren's Syndrome
Adelphi Primary Sjogren's Syndrome (pSS) Disease Specific Programme (DSP)
Sjogren's Syndrome is a chronic autoimmune disease characterized by sicca (dryness) symptoms of the mouth and eyes. This autoimmune disease is less commonly studied and there are no licensed treatments to treat the underlying…
- Trial name
- NCT03501420
- Testing
- Interview, PSC questionnaire, PRFs
- Where
- United Kingdom
- Volunteers
- 2,223 people
- Sponsor
- GlaxoSmithKline
Sjogren's Syndrome
Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention
The primary purpose of this study is to quantify the change in expression of biomarkers on the ocular surface of Sjogren's Syndrome participants after treatment with Maxidex.
- Trial name
- NCT00631358
- Testing
- Maxidex, No treatment
- Where
- 2 sites in Canada
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Healthy Volunteers, Sjögren's Syndrome
A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
Primary Sjögren's syndrome (pSS) is a condition when the body's immune system attacks glands that produce fluids, such as the tear and saliva glands. This leads to dry eyes and a dry mouth.
- Trial name
- NCT06544642
- Testing
- ASP5502
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
SLE (Systemic Lupus), Sjogren's Syndrome
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
This is a single arm study to evaluate the efficacy and safety of CD19 targeted CAR-T cells therapy for patients with Refractory Autoimmune Disease
- Conditions
- SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma, Dermatomyositis
- Trial name
- NCT06056921
- Testing
- CD19 targeted CAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Sjögren's Syndrome
A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)
The main purpose of this study is to learn more about the safety and side effects of the study drug known as LY3090106 in participants with Sjögren's Syndrome (SS).
- Trial name
- NCT02614716
- Testing
- LY3090106
- Where
- 7 sites in United States, Bulgaria and 2 more
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye
Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease
The goal of this research is to determine if the Tangible Boost system adequately replenishes the Hydra-PEG coating on the surface of a rigid contact lens.
- Conditions
- Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
- Trial name
- NCT04313725
- Testing
- Tangible Boost
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Tangible Science
Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc
A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases
To evaluate the safety and tolerability of escalating, single subcutaneous doses of MEDI7734 in adult subjects with type I interferon-mediated autoimmune diseases.
- Trial name
- NCT02780674
- Testing
- MEDI7734
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Sjögren, Sjogren Disease
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.
- Conditions
- Sjögren, Sjogren Disease, Sjogren's Syndrome
- Trial name
- NCT07041099
- Testing
- CLN-978
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 36 people
- Sponsor
- Cullinan Therapeutics Inc.
Sjogren's Syndrome (SS)
An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)
Sjogren's syndrome (SS) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary gland inflammation, with resultant dryness of the eyes and mouth and occasional glandular enlargement.
- Trial name
- NCT05217472
- Testing
- Ravaglimab, Ravagalimab
- Where
- Netherlands
- Sponsor
- AbbVie
Dry Eye Disease
Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease
Primary Objectives: To compare the efficacy of cenegermin vs vehicle in Schirmer I test (without anaesthesia) > 10 mm/5 min at Week 4 by testing the superiority.
- Trial name
- PROTEGO-2 (NCT05136170)
- Testing
- Cenegermin, Vehicle
- Where
- 10 sites in United States, Italy
- Volunteers
- 85 people
- Sponsor
- Dompé Farmaceutici S.p.A
Sjogren's Syndrome
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.
- Trial name
- NCT04968912
- Testing
- Nipocalimab, Standard of Care Treatment
- Where
- 69 sites in United States, France and 8 more
- Volunteers
- 163 people
- Sponsor
- Janssen Research & Development, LLC
Xerostomia, Sjogren's Syndrome
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness
The primary objective of this clinical study is to determine the impact of P-552 oral rinse on salivary volume after administration of a single dose of P-552and versus vehicle rinse.
- Trial name
- NCT01369589
- Testing
- P-552
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Parion Sciences
Dry Eye Syndromes, ATD
Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease
The objective of this study is to evaluate the safety and effectiveness of Viveye OMNS non-invasive treatment for management of the signs and symptoms of severe dry eye disease.
- Conditions
- Dry Eye Syndromes, ATD, Sjogren's Syndrome
- Trial name
- OMNS (NCT04143841)
- Testing
- Viveye OMNS treatment
- Where
- 3 sites in Israel
- Volunteers
- 50 people
- Sponsor
- Epitech Mag Ltd.
SLE (Systemic Lupus), Systemic Sclerosis
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CD19 or CD19-BCMA CAR-T in patients with active SLE, SSc, AAV…
- Conditions
- SLE (Systemic Lupus), Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT06548607
- Testing
- CD19 or CD19-BCMA CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Sjögren´s Disease
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
The purpose of this study is to demonstrate the efficacy and safety of ianalumab (VAY736) 300 mg administered subcutaneously (s.c.) monthly for 52 weeks in adult participants with Sjögren's disease who have high symptom burden.
- Trial name
- THALASSA (NCT07621809)
- Testing
- VAY736
- Where
- 33 sites in United States, Australia and 6 more
- Volunteers
- 570 people
- Sponsor
- Novartis Pharmaceuticals
Sjogrens Syndrome
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjögren's syndrome who have previously completed treatment from one of two NEPTUNUS 1 year core studies (CVAY736A2301…
- Trial name
- NEPTUNUS-Ext (NCT05985915)
- Testing
- Ianalumab (VAY736)
- Where
- 198 sites in United States, Argentina and 33 more
- Volunteers
- 612 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Sjogren's Syndrome
Clinical Performance of BioCLIA Ro60
The study is to evaluate the clinical performance of BioCLIA Ro60 for measuring the autoantibody in autoimmune disease patients.
- Trial name
- NCT03204448
- Testing
- BioCLIA Ro60
- Where
- United States
- Sponsor
- HOB Biotech Group